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. The JmjC-domain-containing protein ubiquitously transcribed tetratricopeptide repeat, X-linked (UTX), which demethylates dimethylated as well as trimethylated histone H3 Lys27 (H3K27me3) 2 , is a frequent target of somatic loss-of-function mutations in multiple cancer types [3] [4] [5] [6] [7] [8] including leukemia [9] [10] [11] [12] . Reintroduction of intact UTX into mutation-bearing cancer cells leads to significant transcriptional changes and a decrease in proliferation 7 , in keeping with UTX's role as a tumor suppressor. However, the mechanisms by which UTX suppresses malignancy are poorly understood. Mechanistic insights into the tumor-suppressive function of UTX have come from studies of T-cell acute lymphoblastic leukemia (T-ALL), in which an absence of UTX catalytic function is crucial for T-ALL initiation and maintenance 9 . Importantly, UTX mutations in T-ALL are found almost exclusively in males, reflecting the fact that the gene is X linked and escapes X inactivation 13 , such that females (but not males) with single-allele loss-of-function UTX mutations retain UTX expression 14 . Interestingly, T-ALL mutations are concentrated in the catalytic JmjC domain, whereas this bias is not seen in other cancers in which the mutations are spread throughout the gene 15 , thus raising the possibility of different tumor-suppressive mechanisms. Of potential relevance, UTY, the Y-chromosome homolog of UTX, has markedly lower demethylase activity, owing to point substitutions affecting substrate binding 16 . In contrast, in common with UTX, UTY contains an intact tetratricopeptide-repeat region that is involved in protein-protein interactions and mediates demethylase-independent functions 17 . Tantalizingly, deletion of UTY is seen more frequently than expected in cancer cell lines with mutations in UTX than in those without , Konstantinos Tzelepis 1 , raising the possibility of a functional redundancy between the two paralogs.
Using myeloid malignancies as an exemplar, we investigated the role of Utx loss in oncogenesis and its interaction with Uty in mice after hematopoietic-specific loss of Utx. Our findings showed that UTX prevents leukemogenesis through coordinate repression of pro-oncogenic E-twenty-six (ETS) and maintenance of tumorsuppressive GATA transcriptional programs. These functions are mediated by differential effects on genome-wide acetylated H3 Lys27 (H3K27ac), monomethylated H3 Lys4 (H3K4me1) and chromatin accessibility, and their functional consequences were found to be rescued by both UTY and enzymatically dead UTX, thereby confirming their independence from demethylase activity.
Results
Homozygous loss of Utx induces spontaneous leukemia in a mouse model. To investigate the function of UTX in the hematopoietic system, we generated conditional-Utx-knockout mice, in which exon 3 of Utx is flanked with loxP sites (Utx f/f ) 18 ( Fig. 1a) . Utx f/f mice were crossed into the inducible Mx1-Cre line, thus enabling efficient Utx recombination in hematopoietic stem and progenitor cells (HSPCs) after treatment with polyinosinic-polycytidylic acid (pIpC), which activates the Mx1 promoter. Utx f/f ; Mx1-Cre mice treated with pIpC (hereafter denoted Utx −/− mice) showed loss of Utx mRNA and protein (Fig. 1b,c Fig. 1d ). At necropsy, the Utx −/− mice had significantly higher spleen weights ( Fig. 1e ) and a predominance of myeloid cells in the spleen and bone marrow (BM) (Fig. 1f ). Blood leukocyte counts (WBC) showed a variable rise, and both platelet (PLT) and hemoglobin (HGB) levels were lower than those in Utx +/+ mice ( Supplementary Fig. 1a -c). Histological examination showed that most of the mice (63%) developed acute myeloid leukemia (AML) (Fig. 1g,h ). In contrast, no Utx +/− or Utx +/+ mice developed AML. Splenocytes from leukemic Utx −/− mice propagated the disease in secondary recipients (Fig. 1i) , thus verifying their full leukemogenic potential. Exome sequencing of seven Utx −/− AMLs showed no recurrently mutated genes, with the exception of Skint11 (two of seven samples), and only occasional copy number alterations ( Supplementary Fig. 1d-f ). To more accurately mimic human disease, we expressed the AML1-ETO fusion gene, which commonly co-occurs with UTX mutations 10, 19, 20 , in Utx −/− HSPCs, and observed significantly reduced survival of recipient mice ( Supplementary Fig. 1g-i) .
Deregulation of HSPC number, function and differentiation after Utx loss. Our findings suggested that Utx loss confers a preleukemic state on HSPCs, and transformation depends on additional mutations. To characterize this preleukemic phase, we analyzed mice early after Utx deletion (4-5 weeks after pIpC). As reported previously 21 , Utx −/− mice, compared with Utx +/+ and Utx +/− mice, demonstrated splenic enlargement (Fig. 2a,b) . We next examined the effect of UTX on hematopoietic differentiation and the composition of the HSPC compartment, likely to harbor the initial target cell for transformation. Utx −/− mice demonstrated a significant expansion of HSPC progenitors (lineage negative, Lin -) (Fig. 2c) , a raised long-term and short-term hematopoietic stem cell (LT-HSC and ST-HSC, respectively) frequency ( Fig. 2d and Supplementary Fig. 2a ), an increase in the granulocyte-monocyte progenitor (GMP) and common myeloid progenitor (CMP), and a decrease in the megakaryocyte-erythroid progenitor (MEP) compartments (Fig. 2e,f and Supplementary Fig. 2b ), as well as a significant decrease in common lymphoid progenitors (CLPs) (Fig. 2g and Supplementary Fig. 2c ). To assess HSPC function, we performed serial replating assays and observed enhanced self-renewal and proliferative potential of Utx −/− progenitors ( Fig. 2h and Supplementary  Fig. 3a) . Regarding mature-cell numbers in BM, spleen and blood, only peripheral-blood thrombocytopenia was noted at 5 weeks after pIpC ( Supplementary Fig. 3b-d) . However, at later time points (36 weeks after pIpC) in otherwise healthy animals, there was also an increase in peripheral-blood MAC1
+ myeloid cells and total WBC, and a decrease in B cells and platelets in Utx −/− compared with Utx +/+ mice ( Supplementary Fig. 3e-g ). Collectively, these results demonstrate that biallelic loss of Utx leads to dramatic and progressive alterations in the composition, function and differentiation of HSPCs and their progeny, including enhanced self-renewal, myeloid expansion and a block in lymphoid and erythroid/megakaryocytic differentiation (Fig. 2i) .
UTY also suppresses leukemia induction and rescues UTXdeficient preleukemic phenotypes. To define a possible role of UTY in suppressing leukemogenesis, we also monitored hemizygous (Utx -/Y , lacking Utx but expressing Uty) and control (Utx +/Y ) male mice over the same time period. Remarkably, and in stark contrast to Utx −/− females, Utx -/Y males showed no differences in survival or hematological phenotype as compared with those of Utx +/Y mice ( Fig. 2j ). In particular, we observed no differences in spleen and liver weights, WBC counts, or platelet and hemoglobin levels (Supplementary Fig. 3h-l) . Moreover, no Utx -/Y mice developed AML, thus indicating that UTY also suppresses myeloid leukemogenesis (Fig. 2k) . Similarly, the presence of UTY in hemizygous males was sufficient to abrogate the abnormalities in preleukemic HSPCs, apart from decreases in the MEP and CLP compartments ( Fig. 2l and Supplementary Fig. 4a-i) . Importantly, CRISPRCas9-mediated knockout of Uty in Utx -/Y mice increased HSPC self-renewal, thus recapitulating the phenotype of Utx −/− female mice (Fig. 2m,n) .
Because the only significant difference between UTY and UTX proteins is the lack of catalytic activity in the former, these findings suggested that catalytic activity is dispensable for their tumorsuppressor functions. To further test this hypothesis, we identified an AML cell line, MONO-MAC6, with deletion of both UTX and UTY. Lentiviral expression of UTX, UTY or a catalytically dead UTX mutant (UTX-MT2) 22 in MONO-MAC6 cells confirmed this hypothesis: all constructs significantly suppressed proliferation in vitro (Fig. 3a-c) . In xenotransplantation assays, MONO-MAC6 cells expressing UTX, UTX-MT2 or UTY, compared with FLAGexpressing control cells, demonstrated slower growth and significantly longer recipient survival (Fig. 3d-f) . Together, these studies demonstrate that the tumor-suppressor functions of UTX do not require its catalytic activity and are shared with its catalytically inactive paralog UTY.
Concomitant loss of both UTX and UTY tumor suppression occurs in multiple human cancer types. Our findings indicate that UTY can suppress myeloid leukemogenesis; however, unlike T-ALL 14 , UTX-mutated AML shows no sex bias. We therefore analyzed the status of UTY in human male AML cell lines carrying UTX mutations, identified through the COSMIC database (Fig. 3g) . We confirmed loss of UTY expression in all four studied male AML lines with UTX mutations/deletions (Fig. 3h) . Analysis of exome-sequencing data from COSMIC showed that all lines contained a UTY microdeletion. Systematically extending our analysis, we identified an additional seven male hematopoietic cell lines with UTX mutations, of which four lines had UTY microdeletions (Supplementary Table 1 ). Strikingly, in informative solid organ cancers, 20/25 (80%) UTX-mutant male cell lines also demonstrated UTY microdeletion/mutation (Supplementary Table 1) , and we confirmed loss of UTY expression in a subset (10/13; Fig. 3i ). (n = 9) mice; mean ± s.e.m. is shown; n, number of mice per genotype; P by one-way analysis of variance (ANOVA) with Bonferroni correction, t = 2.554, df = 55. f, Characteristic MAC1/GR1 flow cytometry analysis of BM and spleen (Sp) cells from one diseased Utx −/− mouse (similar results were observed in n = 12). g, Histopathological diagnoses of moribund mice of the indicated genotypes. The number of mice with a cancer diagnosis and the total analyzed are indicated for each genotype. B-ALL, B-cell ALL; AL, acute leukemia, unclassified; MPN, myeloproliferative neoplasm; other, nonhematological tumors; other (n/s), nonspecified. h, Characteristic histology from one mouse with AML (similar results were observed in n = 20 mice). Sp, spleen; Li, liver. i, Kaplan-Meier survival curves of mice transplanted with Utx −/− leukemias: AL (n = 5), T-ALL (n = 5) and two AML (n = 9). -/Y males, we removed these 673 genes from subsequent analysis. Focusing on mRNAs differentially expressed with a log 2 fold change (FC) above 0.5 or below -0.5, we identified 2,686 genes (Fig. 4a,b) . Interestingly, and somewhat counterintuitively to the perception of UTX as solely a transcriptional activator, similar numbers of genes were upregulated (1,517, 57%) and downregulated (1,169, 43%) after Utx loss. Importantly, although additional genes were also differentially expressed after evolution to frank AML in Utx −/− mice, substantial components of the preleukemic transcriptional programs were retained ( Fig. 4c and Supplementary Table 5 ). Using ChIP-seq in wild-type mice, we documented 8,304 UTX-binding sites, corresponding to 6,734 genes (Supplementary Table 6 ), most of which were found at the promoter or within the gene body (Fig. 4d) . Correlation with gene expression demonstrated that 581/1,169 (50%) of downregulated and 614/1,517 (40%) of upregulated gene loci were bound by UTX (Supplementary Table 7) , thus suggesting that approximately half of the deregulated genes are direct UTX targets (Fig. 4e ) and supporting the view that UTX can be a transcriptional activator or repressor.
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In keeping with our finding that H3 Lys27-demethylase activity is redundant for tumor suppression, only 302 differentially modified H3K27me3 peaks were observed between Utx −/− and Utx
HSPCs. Further corroborating this notion, the majority (200/302, 67%) also showed decreased rather than increased modification (Fig. 4f and Supplementary Table 8 ). In marked contrast, the coordinated acetylation at the same lysine residue, H3 Lys27, was markedly altered in its distribution in Utx −/− compared with Utx +/+ mice. We observed 5,121 regions with differential H3K27ac in either direction (corresponding to 2,916 gene loci), including 3,442 peaks (2,054 gene loci) significantly decreased and 1,679 (953 gene loci) increased, after UTX loss ( Fig. 4g and Supplementary Tables 9 and 10). Comparing these putative enhancer regions to a recently published promoter-based capture-HiC dataset in the HSPC cell line HPC7 (ref. 23 ), we observed that 23% of upregulated and 32% of downregulated regions interacted with promoters ( Supplementary  Fig. 5a-c) , thus suggesting substantial enhancer remodeling after UTX loss. The observed changes were locus specific, because global levels of H3K27ac and H3K27me3 were similar between Utx +/+ and Utx −/− BM ( Supplementary Fig. 5d ). To define direct co-occurrence on chromatin, we overlapped UTX peaks and differential H3K27ac regions. However, we found only a modest co-occurrence, with only 282/5,121 regions (6%) in common ( Supplementary Fig. 5e ). UTX peaks and regions with differential H3K27ac were then annotated to their associated/adjacent genes, thereby defining larger genomic areas for comparison. In contrast to the limited peak-topeak co-occurrence, when we compared whole gene loci showing differential H3K27ac and UTX binding, we identified a highly significant overlap of 1,396/2,916 regions (48%, Supplementary  Fig. 5f and Supplementary We observed 4,552 differentially modified H3K4me1 peaks (Fig. 4h and Supplementary Table 12) , most of which (3,898) were downregulated in Utx −/− mice. Differentially downregulated H3K4me1 regions highly correlated with peaks that also lost H3K27ac (1,589 common peaks, 46% overlap). UTX did not bind directly at these sites, thus suggesting an indirect role of UTX and the COMPASS complex in early enhancer specification. Together, these data confirm that H3K27 demethylase activity is dispensable for tumor suppression, identify UTX as both a transcriptional activator and repressor and suggest that UTX/COMPASS-mediated indirect regulation of enhancers is important for transformation.
Loss of Utx activates an oncogenic ETS transcriptional program during leukemia development. As our genomic data demonstrated both loss and gain of activating chromatin marks and upand downregulation of gene expression after Utx loss, we speculated that both processes might be necessary for leukemia development but mediated by different mechanisms. We therefore analyzed up-and downregulated gene programs separately. Notably, several genes encoding ETS transcription factors, including Elf4, Etv6, Erg, Fli1, Ets2, Spi1 and Elk3 were upregulated immediately after Utx loss in the preleukemic phase (Fig. 5a ). Importantly, overexpression of these ETS factors persisted in Utx −/− AML (Fig. 5b) . Gene-set enrichment analysis (GSEA) also demonstrated a significant correlation between upregulated preleukemic transcriptional programs and genes repressed after knockdown of the oncogenic ETS-factor fusion EWSR1-FLI1 (Fig. 5c ). In addition, motif analysis of 614 UTX-bound and upregulated genes demonstrated a significant enrichment in ETS-binding motifs ( Fig. 5d and Supplementary Supplementary Fig. 5g ). These data suggest enhanced ETS-factor binding and transcriptional autoregulation of specific ETS genes in the absence of Utx. On a global scale however, UTX binding did not colocalize with PU.1 chromatin occupancy (only 115 peaks/14,198, 0.8%), thus suggesting that the profound general redistribution of PU.1 binding may relate more to its overexpression. ETS factors are known to recruit histone acetyltransferases 25 and consequently increase H3K27ac deposition. Therefore, we next asked whether the changes in differential H3K27ac and H3K4me1 observed in Utx −/− might correlate with UTX-dependent redistribution of PU.1 binding. Indeed, we observed that 51% of gained H3K4me1 (335/654) and 30% of gained H3K27ac (470/1,679) peaks also demonstrated increased PU.1 binding ( Supplementary Fig. 6a,b) . These directbinding data provide a mechanistic explanation for the gain of enhancer marks after Utx loss.
To investigate the functional importance of deregulated ETS factors, we used CRISPR-Cas9 genome editing to ablate several of these factors in Cas9-expressing, UTX/UTY-mutant, MONO-MAC6 cells. Importantly, we observed substantial growth suppression after editing of the same ETS factors overexpressed immediately after Utx loss: FLI1, ERG, SPI1 (PU.1), ETS1, and ELF4 (Fig. 5e ). These data indicate that ETS factors drive leukemia induction and maintenance in the context of UTX/UTY loss.
Utx loss affects BRG1SMARCA4-dependent chromatin remodeling, thereby repressing a tumor-suppressive GATA program during leukemia development. GSEA of the downregulated gene-expression program demonstrated enrichment in GATA2 targets (Fig. 5f) Table 14) . To better understand the indirect effects of UTX on acetylation changes at GATA and ETS sites, we performed pulldown of endogenous UTX in the mouse myeloid cell line 416B and subsequent mass spectrometric analysis. We did not observe UTX interaction with ETS factors or GATA2, but we did identify multiple known UTX interactors, including KMT2C/D and other COMPASS members (Fig. 5h and Supplementary Tables 15 and 16 ). Interestingly, our proteomic analysis also demonstrated lower-level interactions between UTX and the ATP-dependent chromatinremodeling-complex members SMARCA4 (BRG1) and CHD4, which we further verified ( Supplementary Fig. 6f ). Speculating that changes in acetylation and GATA binding occurred through alterations in chromatin accessibility, we performed ATAC-seq analysis in preleukemic Utx −/− HSPCs and Utx +/+ controls. Strikingly, we observed significant and bidirectional changes in chromatin and Utx -/Y male (n = 2 mice) compared with sex-matched wild-type controls (n = 2 mice); genes with adjusted (adj.) P < 0.05 are shown. Subtraction of genes differentially expressed in males versus females defines a differential transcriptional program of interest; log 2 fold change (FC) (-0.5 > log 2 FC > 0.5). b, Volcano plot of log 2 FC (-0.5 > log 2 FC > 0.5) and adjusted P < 0.05 (only transcripts with P values between 0.05 and 1 × 10 −38 are shown) for genes differentially expressed in the preleukemic and AML setting. In a and b, P values were generated with a negative binominal generalized linear model (DESeq2). c, Overlap between differentially expressed genes in Utx −/− preleukemic HSPCs (n = 2 mice) and AMLs (n = 3 mice), each compared to Utx +/+ HSPCs (n = 2 mice); P by hypergeometric test. Down, decreased genes or peaks; up, increased genes or peaks. d, Distribution of UTX ChIP-seq peaks in annotated regions of the genome. e, Highly significant enrichment of UTX-bound genes among those differentially expressed in preleukemic Utx −/− HSPCs; P by hypergeometric test. f-h, H3K27me3 (f), H3K27ac (g) and H3K4me1 (h) density plots (left) and average read counts (right) across all (global changes) or differentially modified regions (local changes). H3K27me3 signal density shows that only 302 genomic regions were differential modified, in contrast to similar plots revealing 5,120 differential modifications for H3K27ac and 4,552 differential modifications for H3K4me1 Motif Name P value 1.
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Gata:Scl Table 30 ). c,d, Genomic snapshot of GATA2, UTX, ATAC-seq and H3K27ac ChIP-seq in Utx +/+ and Utx −/− HSPCs at the Ets2 (c) and Steap3 loci (d). Colocalization of GATA2 binding with dynamically closed chromatin and loss of H3K27ac after UTX loss were found without evidence of GATA2-UTX cobinding. In contrast, binding of the chromatin remodelers SMARCA4 BRG1 and CHD4 directly colocalized with UTX binding (lower two tracks). At the Ets2 locus, newly accessible chromatin was also seen after UTX loss, again at regions not directly bound by UTX or chromatin remodelers. e, Density plots of UTX, BRG1SMARCA4 and CHD4 ChIP-seq on UTX-bound genomic loci; Venn diagram shows overlap among all UTX, BRG1SMARCA4 and CHD4 ChIP-seq peaks; P by Fisher's exact test for ChIP-seq: UTX versus BRG1SMARCA4/CHD4. f, Schematic representation of PU.1 occupancy occurring mostly on closed chromatin. g, Overlap of genes associated with enhanced PU.1 binding (in Utx −/− ) on closed chromatin with gene expression changes from preleukemia (PL) to AML. For PU.1 ChIP-seq, n = 3 mice; ATAC-seq, n = 3 mice; PL RNA-seq, n = 2 mice; AML RNA-seq, n = 3 mice. P by hypergeometric test. h, Genomic snapshot demonstrating an enhanced PU.1 occupancy in Utx −/− HSPCs that occurs on closed chromatin at the Rab11a locus and a correlation with PL and AML RNA-seq. Rab11a expression increased only after progression to AML. Tables 17 and 18 ). Loss of chromatin accessibility correlated strongly with decreased H3K27ac (2,274/3,442 peaks, 73%) and H3K4me1 deposition (2,264/3,898, 58%) ( Supplementary  Fig. 7a,d ) and decreased gene expression ( Supplementary Fig. 7b and Supplementary Table 19 ). Furthermore, analysis of closed chromatin sites showed a striking enrichment in GATA motifs ( Fig. 6a and Supplementary Fig. 7a,b) . Comparisons of GATA2 peaks in HPC-7 (ref. Fig. 7c ). We next asked whether UTX binds with BRG1SMARCA4 and CHD4 on chromatin. Importantly, we observed a highly significant overlap (91%, 7,541/8,304 peaks) of UTX sites with binding of both BRG1SMARCA4 and CHD4 from published ChIP-seq data 27 ( Fig. 6c-e) . To validate co-occupancy, we used CRISPR-Cas9 genome editing of Utx in 416B cells targeting Utx exon-3, recapitulating our mouse model. We observed significantly lower chromatin binding for BRG1 SMARCA4 and CHD4 at exemplar loci (Aff1 and Lrrc8c) in the absence of UTX, in keeping with a role of UTX in the recruitment of complexes containing these proteins ( Supplementary Fig. 7e-g ).
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To further address the molecular mechanism of UTX-dependent chromatin remodeling, we analyzed the activity of BRG1SMARCA4 and CHD4 in Utx −/− and Utx +/+ HSPCs. We crossed Utx f/f ; Mx1-Cre mice with Cas9-expressing mice 28 and induced Utx deletion. Five weeks after gene deletion, we isolated HSPCs and used CRISPR-Cas9 genome editing to target Smarca4 and Chd4, using an empty guide RNA (gRNA) construct as control. We then analyzed chromatin accessibility through ATAC-seq, hypothesizing that loss of Smarca4 and/or Chd4 would at least partially mimic the effects of UTX loss. We found 1,150 sites with significantly decreased accessibility after Smarca4 editing and only 16 sites with increased accessibility, thus suggesting that SMARCA4 is mainly involved in the opening or maintenance of specific open chromatin loci (Supplementary Table 20 ). We then overlapped these sites with regions that were differentially lost between Utx +/+ versus Utx −/− cells, using the same culture conditions (2,871 peaks; Supplementary Table 21) . We observed that 21% (244/1,150) of regions closed in Smarca4-edited cells overlapped with sites that closed after Utx deletion ( Supplementary Fig. 8a,b) . Of note, there was no further alteration in accessibility at these 244 sites when Smarca4 was edited in Utx −/− cells (Supplementary Table 22 ). This result suggests a degree of functional redundancy between UTX and SMARCA4 loss for chromatin accessibility. Performing motif analysis of these 244 sites, we again observed high enrichment in GATA motifs ( Supplementary  Fig. 8a,b) . Similar analysis for CHD4 demonstrated no significant overlap after Utx loss ( Supplementary Fig. 8c and Supplementary  Table 23 ). These findings, along with our proteomic data, suggest that UTX interacts with SMARCA4 and subsequently maintains chromatin accessibility at GATA-bound regions.
Utx loss allows chromatin accessibility to other transcription factors and facilitates the pioneering function of ETS factors during AML evolution. For sites newly accessible by ATAC-seq following Utx loss, the converse was seen, with a correlation between these sites and increased H3K27ac (766/1,679 peaks, 45%; Supplementary  Fig. 9a ), H3K4me1 (438/654 peaks, 67%; Supplementary Fig. 9b ) and gene expression close to the accessible sites (389/1,517, 25%; Supplementary Fig. 9c and Supplementary Table 24) . Furthermore, motif analysis of newly accessible sites showed enrichment in several transcription factors including ASCL1, E2A, EBF, PTF1a and TCF12, in addition to ETS factors (Fig. 6b) . Three transcription factors represented in the top five motifs (ASCL1, EBF and PTF1A) were not expressed in MONO-MAC6 cells. Assessing the functional relevance of the two remaining expressed TFs, TCF3 (E2A) and TCF12 (HEB), we used CRISPR-Cas9 editing in MONO-MAC6 cells and observed a significant decrease in cell growth after knockout of either TCF3 or TCF12 (Supplementary Fig. 9d ). These data suggest that the transcriptional activity of TCF3 and TCF12 maintain AML growth in the absence of UTX. In assessing ETS sites, PU.1-binding sites gained in the absence of UTX only minimally overlapped with open chromatin at the preleukemic stage (758/8,329 peaks, 9%). However, of interest, although the remaining 91% (7,592 peaks, linked to 3,450 genes) occurred in ATACinaccessible chromatin in the preleukemic stage and had no effect on gene expression after Utx loss, we documented that the expression of 691 of these linked genes (20%) was upregulated in the later transition to AML (Fig. 6f-h and Supplementary Tables 25 and 26 ). These data suggest that the pioneering function of redistributed ETS TFs 'primes' a later leukemogenic transcriptional program for upregulation during AML evolution.
Discussion
The mechanism of tumor suppression by UTX has previously been thought to be dependent on its demethylase catalytic function, a notion supported by data in T-ALL 9, 14 . However, during the evolution of AML, we demonstrated that the demethylase function of UTX is redundant for tumor suppression. Noncatalytic functions of UTX have previously been demonstrated in embryonic development 22, 29, 30 and in mammary luminal lineage development 31 . UTX catalytic activity has been reported to upregulate expression of the master transcription factor PLZF and to modulate superenhancer accessibility in invariant natural killer T cells 32 . Additionally, UTX function has recently been linked to enhancer activity and gene activation via coordination of COMPASS-mediated H3K4me1 deposition and CREBBP/p300-mediated H3K27ac deposition 33 , as also demonstrated here. However, no role of these functions in tumor suppression had previously been demonstrated. Furthermore, our study confirms and defines the molecular basis for the frequent co-occurrence of UTX and UTY mutation/loss 6, 7 , identifying UTY as a tumor suppressor in its own right and highlighting noncatalytic functions of UTX/UTY as the dominant mediators of tumor suppression.
Contrary to the prevailing perception that UTX is solely a transcriptional activator 17 , our study identified that it can also function as a repressor. We demonstrated that its loss leads to substantial alterations in chromatin accessibility, bidirectional alterations in H3K27ac, a predominant loss of H3K4me1, and coordinated changes in gene expression that impart proleukemic properties on HSPCs and that are maintained during evolution to AML ( Supplementary Fig. 11 ). In particular, UTX loss upregulates a transcriptional program driven by the ETS family of pioneer transcription factors [34] [35] [36] . ETS factors are known to be oncogenic 37, 38 . Overexpression of a single ETS factor, ERG, is able to generate AML in mice 39 , and ERG expression levels are one of the strongest prognostic factors in human AML 40 . Novel binding events of the exemplar ETS factor PU.1 lead to an increase in chromatin accessibility, activation of enhancer modifications and, via its pioneering activity, gene activation occurring at later time points during leukemia evolution. Furthermore, loss of UTX also downregulates a program of GATA-driven genes through loss of chromatin accessibility and loss of local H3K27ac. GATA factors are also critical regulators of hematopoiesis and leukemia 41 , and germline and somatic loss-of-function mutations of GATA2 have been described in AML 42, 43 . Together, our data demonstrate that UTX loss coordinates a 'double-hit' mechanism reminiscent of the genomic inversion that removes a critical enhancer and consequently downregulates GATA2 expression and relocates it, thereby driving oncogenic expression of the transcription factor EVI1 (ref.
44
).
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Our proteomic data also suggest that noncatalytic tumor-suppressive functions operate through protein-protein interactions with tetratricopeptide repeats, the other major protein domain of UTX/UTY 17 . We demonstrated protein interactions between endogenous UTX and the KMT2C/D-containing COMPASS complex and the ATP-dependent chromatin remodeling factors SMARCA4 and CHD4 in myeloid cells. The interaction between UTX and SMARCA4 has been demonstrated in T lymphocytes 45 and during cardiac development 46 . Loss of Utx led to a marked decrease in the deposition of the canonical early enhancer mark H3K4me1. Notably, mutations of KMT2D are responsible for most (60-80%) cases of Kabuki syndrome, whereas UTX mutations cause ~10% of cases, thus highlighting the mechanistic links between the two proteins. Furthermore, we demonstrated co-occupancy of UTX, SMARCA4 and CHD4 (ref. 27 ) at specific genomic loci associated with alterations in chromatin accessibility after UTX loss (Fig. 6c-e) .
In addition, we functionally demonstrated that SMARCA4 loss at least in part recapitulated the phenotype of loss of chromatin accessibility seen after Utx deletion. Recent studies have demonstrated that H3K4me1 is required for binding of the SMARCA4-containing BAF complex to chromatin and enhances BAF chromatin-remodeling activity 47 . Our own data corroborate and extend this model, further defining a role for UTX in linking H3K4me1 deposition with chromatin remodeling via SMARCA4. Altogether, these mechanistic data demonstrate that loss of UTX leads to an upregulated activity of ETS transcription factors with both immediate and later pioneering effects, thus facilitating chromatin accessibility, as well as loss of coordination of COMPASS-mediated H3K4me1 enhancer specification and SMARCA4-mediated chromatin accessibility. Together, these responses lead to altered patterns of gene expression that induce and maintain leukemia ( Supplementary Fig. 11 ).
Our findings identify UTX as a complex transcriptional regulator capable of activating or repressing transcription, through effects on pioneering transcription factors, enhancer function and chromatin accessibility. These results have obvious implications regarding the role of UTX in tumor suppression and other critical cellular processes. Finally, our framing of UTY as a bona fide tumor-suppressor gene establishes a pathogenic role of Y-chromosome-specific genes in carcinogenesis, and sheds new light on the role of Y-chromosome loss in diverse cancer types and on the importance of age-related clonal hematopoiesis associated with 'loss of Y' in otherwise healthy men [48] [49] [50] . Protein extraction, immunoblotting and coimmunoprecipitation. The cells were lysed in whole-cell lysis buffer (50 mM Tris-HCl, pH 8, 150 mM NaCl, 0.1% NP-40 and 1 mM EDTA) supplemented with 1 mM DTT, protease inhibitors (Sigma) and phosphatase inhibitors (Sigma). Protein concentrations were assessed with Bradford assays (Bio-Rad), and an equal amount of protein was loaded per track. Before loading, the samples were supplemented with SDS-PAGE sample buffer, and DTT was added to each sample. 10-40 µ g of protein was separated on a 10% SDS-PAGE gel and blotted onto polyvinylidene difluoride membranes (Millipore). The following primary antibodies were used: anti-UTX (Bethyl, A302-374A), anti-UTX (GeneTex, GTX121246) and anti-IgG (Santa Cruz Biotechnology, sc-2027); anti-α -tubulin (Sigma, T6074) or anti-ACTIN (Santa Cruz Biotechnology, sc-1616) was used as a loading control. The secondary antibodies used in the study were as follows: HRP-linked donkey anti-rabbit (GE Healthcare UK, NA934) and ECL HRP-linked anti-mouse (Santa Cruz Biotechnology, sc-2005). Visualization was performed with LumiGLO Chemiluminescent Substrate (KPL, 54-61-00). Coimmunoprecipitation was performed on the extracts isolated with cell lysis buffer (described above). 2-6 μ g of antibody was bound to 20 µ l of Dynabeads Protein G (Thermo Fisher Scientific) and incubated with 500-1,000 µ g of freshly extracted protein for 1.5 h at 4 °C with rotation. Immunoprecipitates were washed four times with IP wash buffer (10 mM Tris-HCl, pH 8, 150 mM NaCl, 0.1% NP-40 and 1 mM EDTA) supplemented with protease inhibitor (Sigma). Immunoprecipitation samples with beads were then resuspended in 1× NuPAGE LDS Sample Buffer (Thermo Fisher Scientific) supplemented with NuPAGE Sample Reducing Agent (Thermo Fisher Scientific). The following antibodieswere used for immunoprecipitation; anti-CHD4 (Abcam, ab72418), anti-BRG1 (Santa Cruz Biotechnology, sc-10768) anti-UTX (Bethyl, A302-374A) and IgG (Santa Cruz Biotechnology, sc-2027).
URLs
Histological analysis of mouse tissue. The tissues were fixed in 10% formaldehyde and were subsequently paraffin embedded. Bones were decalcified with 0.38 M EDTA pH 7. Tissue sections (4 µ m) were stained with hematoxylin and eosin (Thermo Fisher Scientific). Histology assessment was performed with the Bethesda criteria for mouse hematological tumors 51, 52 .
Blood-count analysis. Blood-count measurement was performed on a VetabC analyzer (Horiba ABX). Culture of mouse hematopoietic progenitors. Primary mouse cells were cultured in X-VIVO 20 medium (Lonza) supplemented with 5% serum (Stem Cell Technologies), IL3 (10 ng/ml; Peprotech), IL6 (10 ng/ml; Peprotech), SCF (50 ng ml/ml; Peprotech) and 1% penicillin-streptomycin-glutamine (Gibco). 
Isolation of mouse hematopoietic progenitors. Freshly isolated BM was
Plasmids and cloning.
Plasmids for expression of FLAG-tagged versions of UTX, UTY, UTX-MT2 were purchased from Addgene (pCS2-UTX-F 24168, pCS2-UTY-F 17439 and pCS2-UTX-F-MT2 40619). The lentiviral UTX, UTY, UTX-MT2 and FLAG expression vectors were constructed in pKLV-puro as follows. First, the lentiviral backbone vector, pKLV-U6(Flip)gRNA(BbsI)-PGKpuro2ABFP 53 was digested with BbsI and KpnI to remove the U6gRNA(BbsI)-PGKpuro2ABFP cassette. Gibson cloning (NEB) was performed to clone the PCR products for the EF1α promoter, UTX/UTY/UTX-MT2/FLAG cDNA and a puromycin (Puro)-resistance gene with the primers in Supplementary Table 28 . The EF1α promoter was PCR-amplified from a pLVX-EF1α -IRES-ZsGreen1 construct (Clontech, 631982). The Puro-resistance gene was amplified from the pKLV-U6(Flip) gRNA(BbsI)-PGKpuro2ABFP construct. Gibson cloning was performed according to the manufacturer's specifications. Firefly luciferase-expressing plasmid (EF1α -GFP-T2A-Luciferase) was obtained from System Biosciences (BLIV503-MC-1-SBI). AML-ETO9a plasmid was as previously described 54 . For CRISPR-Cas9 experiments, gRNAs were cloned into a BbsI-digested pKLV2-U6gRNA(BbsI) PGKpuro2ABFP backbone 28 . Sequences of gRNAs used in the study are provided in Supplementary Table 29 .
Lentiviral-vector production and transduction. Lentiviruses were produced in HEK293 cells with a ViraPower Lentiviral Expression System (Invitrogen) according to the manufacturer's instructions. Viral supernatants were concentrated by centrifugation at 6,000 g, 16 h, at 4 °C. The cells were transduced by spinoculation (60 min, 800 g, 32 °C) in culture medium supplemented with polybrene (4 µ g/ml; Millipore) and further incubated overnight at 37 °C. The following day, the transduced cells underwent selection on puromycin (1.5 µ g/ml; Sigma) for 3 d. 
AML-ETO9a transplantation. c-KIT
+ cells were isolated from the BM of Utx
and Utx −/− mice and transduced with lentiviral vectors for expression of the AMLETO9a fusion. Then 1 × 10 6 cells were subsequently transplanted into lethally irradiated syngeneic recipient mice (n = 9 or 10 per group).
Secondary transplantation of mouse Utx
−/− leukemias. 1 × 10 6 splenocytes were injected into sublethally irradiated recipient mice: acute leukemia unclassified (n = 5 mice), T-ALL (n = 5 mice) and two AML (n = 9 mice).
RNA extraction and RNA-seq analysis. RNA was extracted from HSPC/Lin -BM cells with an Arcturus Picopure RNA Isolation Kit (Thermo Fisher Scientific) according to the manufacturer's instructions. RNA from mouse primary AML samples was extracted with TRIzol reagent (Thermo Fisher Scientific). RNA from human cell lines was extracted with an RNeasy kit (Qiagen) according to the manufacturer's instructions. An RNA-seq library was generated with a TruSeq Stranded mRNA Sample Prep Kit (Illumina) and sequenced on the Illumina HiSeq2000 v4 platform with 75-bp paired-end sequencing. RNA-seq reads for each library were mapped with TopHat version 2.0.13 against the mouse genome, build GRCm38.68, downloaded via the Ensembl BioMart data-mining tool. HiSeq libraries were aligned with the following options: --keep-fastaorder --no-sort-bam -r 100 -p 12 --library-type fr-firststrand --no-coveragesearch --microexon-search --transcriptome-index = GRCm38.known, where GRCm38.known is a transcriptome index file in GTF format prepared beforehand in an initial single TopHat run without input reads. Raw counts for each gene in the Genome Reference Consortium genome assembly (GRCm38.68) were obtained with Bioconductor package GenomicAlignments version 1.2.2 with mode 'Union' . Differential expression analysis was carried out with these counts in the Bioconductor package DESeq2, version 1.6.3, with a BH independent filtering method with an FDR of 1%; both packages were used according to their vignettes. Fold changes in expression were also calculated in DESeq2 after correction for differences in library sizes. Supplementary Table 27. For SMARCA4, CHD4 and UTX ChIP-qPCR, 416B cells were cross-linked with 2 mM disuccinimidyl glutarate (Sigma) for 30 min at RT, and this was followed by a second cross-linking with 1% FA for 10 min at RT. Cross-linking was stopped by addition of 125 mM glycine. Cells were resuspended in ChIP Lysis Buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8, and protease inhibitors) and sonicated in a Bioruptor Pico instrument (Diagenode) for ten cycles. Sonicated chromatin was diluted 1:10 in modified RIPA buffer (1% Triton X-100, 0.1% deoxycholate, 90 mM NaCl, 10 mM Tris-HCl, pH 8, and EDTA-free protease inhibitors) and incubated overnight with 3 μ g of anti-SMARCA4 (Santa Cruz Biotechnology, sc-10768x) or anti-CHD4 (Abcam, ab72418). Next, protein A/G (50% A 50% G) Dynabeads (Invitrogen) were added to the chromatin and incubated 2 h at 4 °C, and magnetic separation was then performed. Beads were subsequently washed twice with mixed-micelle buffer (150 mM NaCl, 0.2% SDS, 20 mM Tris-Cl, pH 8.0, 5 mM EDTA, 5.2% sucrose and 1% Triton X-100), high-salt buffer (250 mM NaCl, 5 mM Tris-Cl, pH 8.0, 0.5 mM EDTA, 0.05% sodium deoxycholate, 25 mM HEPES, pH 8.0, and 0.5% Triton X-100) and LiCl buffer (250 mM LiCl, 10 mM Tris-Cl, pH 8.0, 10 mM EDTA, 0.5% NP-40 and 0.5% sodium deoxycholate), then once with elution buffer (1% SDS and 100 mM NaHCO 3 ). Beads were then resuspended in elution buffer supplemented with DNase-free RNase (Roche, 11119915001). Crosslinking was reverted by incubation at 37 °C for 30 min, then at 65 °C overnight. DNA was purified with a Chip-DNA purification kit (Zymo).
Chip-seq, motif analysis, GSEA and data visualization. Adaptor sequences were trimmed for all paired-end reads and mapped against the mm10 reference genome with Bowtie2 (ref. 55 ). All the samples were processed independently, and uniquely mapped reads were retained. Peaks were called with SICER 56 with W200 and G600 for broad peaks and W200 and G200 for narrow peaks. Peak calling was performed for each replicate individually. Motif analyses and peaks were annotated with HOMER 35 . Detailed output of the HOMER motif analyses is included in Supplementary Table 30 . Peaks in intergenic regions were assigned to genes if they were within a 100-kb window from the TSS. Differential binding analysis was performed with DiffBind 57 by grouping replicates together. Overlapping peak analysis was performed with intersect in bedtools 58 . The statistical analysis of the overlapping peaks was performed with Fisher's exact test in bedtools. Each of the ChIP-seq experiments, with the exception of the PU.1 ChIP-seq, was performed in biological duplicate. PU.1 ChIP-seq was performed in biological triplicate. GSEA tools were obtained from The Broad Institute 59 . ChIP-seq, RNA-seq and ATAC-seq data were visualized in UCSC Genome Browser 60 . Venn diagrams were generated with the BioVenn web application 61 . All graphs were generated in GraphPad Prism unless otherwise specified.
Promoter-enhancer interaction analysis. A promoter-associated interaction matrix of multipotent hematopoietic progenitor cell line 7 (HPC-7) was generated in a previous study through a promoter-capture Hi-C method, and data were analyzed in the CHiCAGO package 23 . Genome coordinates from the interaction matrix were converted from mm9 to mm10. In total, 54,339 regions forming significant interactions (CHiCAGO score ≥ 5) with promoter baits were defined as promoter-interacting regions. Differential H3K27ac peaks in Utx −/− versus Utx
were grouped as increased (up) or decreased (down) peaks and intersected with promoter-interacting regions in bedtools. Interactions at specific gene loci were visualized in the WashU Epigenome Browser.
ATAC. The ATAC-seq method was used according to an established protocol 62 with modifications 63 . Briefly, 200,000 cells were washed in 0.3 ml of ice-cold Dulbecco's PBS without calcium and magnesium. The cells were then centrifuged at 300 g for 3 min, resuspended in 400 µ l of freshly made ice-cold sucrose buffer (10 mM Tris-Cl, pH 7.5, 3 mM CaCl 2 , 2 mM MgCl 2 and 0.32 M sucrose) and incubated on ice for 12 min. 10% Triton X-100 was added to a final concentration of 0.5%, and the cells were vortexed briefly before being incubated on ice for a further 6 min to allow access to nuclei. The nuclei were briefly vortexed again before another centrifugation at 300 g for 3 min at 4 °C. The sucrose/Triton lysis buffer was removed, and the nuclei pellets were immediately resuspended in 50 µ l of Nextera tagmentation master mix, comprising 25 µ l 2× Tagment DNA buffer, 20 µ l nuclease-free water and 5 µ l Tagment DNA Enzyme 1 (Illumina FC-121-1030). The tagmentation reaction mixture was immediately transferred to a 1.5-ml low-bind microcentrifuge tube and incubated at 37 °C for 30 min. The tagmentation reaction was stopped by the addition of 500 µ l Buffer PB (Qiagen). The tagmented chromatin was purified with a MinElute PCR purification kit (Qiagen 28004), according to the manufacturer's instructions, with elution in 10 µ l of buffer EB (Qiagen). Then 10 µ l of the tagmented chromatin was mixed with 2.5 µ l Nextera PCR primer cocktail and 7.5 µ l Nextera PCR master mix (Illumina FC-121-1030) in a 0.2-ml low-bind PCR tube. 2.5 µ l of an i5 primer and 2.5 µ l of an i7 primer (Illumina FC-121-1011) were added per PCR, for a total reaction volume of 25 µ l. PCR amplification was performed as follows: 72 °C for 3 min and 98 °C for 30 s, followed by 12 cycles of 98 °C for 10 s, 63 °C for 30 s and 72 °C for 3 min. Libraries were size-selected on a 1% agarose TAE gel, and library fragments from 120 bp to 1 kb were collected. Gel slices were extracted with a MinElute Gel Extraction kit (Qiagen 28604), with elution in 20 µ l Elution Buffer. Samples were further purified with Agencourt AMPure XP magnetic beads (Beckman Coulter A63880) at a ratio of 1.2 AMPure beads:1 PCR sample (vol/vol), according the manufacturer's instructions, with elution in 20 µ l of Buffer EB (Qiagen). Before sequencing, each ATAC-seq library was assessed on an Agilent 2100 Bioanalyzer with a High Sensitivity DNA chip (Agilent Technologies 5067-4626).
ATAC-sequencing analysis. Similarly to ChIP-seq analyses, all the adaptor sequences of ATAC-seq paired-end reads were trimmed, and reads were mapped against the mm10 reference genome in Bowtie2. All the samples were processed independently, and uniquely mapped reads were retained. Peaks were called with MACS2 (ref. 64 ) with -nomodel and -nolambda parameters. Peak calling was performed individually for each replicate. Differential binding analysis was performed with DiffBind 57 by grouping replicates together. Overlapping peak analysis were performed with intersect in bedtools 58 . Statistical analysis of the overlapping peaks was performed with Fisher's exact test in bedtools. ATAC-seq in HSPCs was performed in biological triplicate, and ATAC-seq experiments for remodelers were performed in biological duplicate.
GEO accession codes for publicly available datasets. Data were downloaded from the GEO database under accession codes GSM552234 (GATA2); GSM1296403 and GSM1296404 (CHD4); and GSM1296402 (SMARCA4).
Preparation of IP samples for MS. 10
7 416B cells were lysed in whole-cell lysis buffer (50 mM Tris-HCl, pH 8, 150 mM NaCl, 0.1% NP-40 and 1 mM EDTA), supplemented with 1 mM DTT, protease inhibitors (Sigma), and phosphatase inhibitors (Sigma). Cells were homogenized, and lysates were cleared by centrifugation. UTX immunoprecipitation was performed in whole-cell lysis buffer with 16 µ g of antibody bound to 100 µ l of Dynabeads Protein G (Thermo Fisher Scientific). Samples were incubated for 1.5 h at 4 °C with rotation.
. The peptides were redissolved in 0.5% formic acid and analyzed through online nano liquid chromatography (Ultimate 3000 RSLCnano System) tandem mass spectrometry on an LTQ Orbitrap Velos mass spectrometer. The sample was desalted on a PepMap C18 nano-trap (100 µ m i.d. × 20 mm, 100 Å, 5 µ m), then separated on a PepMap RSLC C18 column (75 µ m i.d. × 250 mm, 100 Å, 2 µ m) in a linear gradient of 4-32% CH 3 CN/0.1% formic acid in 90 min. The HPLC, columns and mass spectrometer were all from Thermo Fisher Scientific. The Orbitrap mass spectrometer was operated in the standard 'top 15' data-dependent acquisition mode while the preview mode was disabled. The MS full scan was set at m/z 380-1,600 with resolution at 30,000 at m/z 400 and AGC at 1 × 10 6 with a maximum injection time at 200 ms. The siloxane ion at 445.120030 was used as the lock mass. The 15 most-abundant multiply charged precursor ions (z ≥ 2), with a minimal signal above 3,000 counts, were dynamically selected for collisioninduced-dissociation fragmentation in the ion trap, which had the AGC set at 5,000 with the maximum injection time at 100 ms. The precursor isolation width was set at 2 Da. The normalized collision energy for collision-induced-dissociation MS/MS was set at 35%. The dynamic exclusion duration time for the selected ions for MS/MS was set at 60 s with ± 10 p.p.m. exclusion mass width. Database search results were further processed with Percolator [66] [67] [68] in Proteome Discoverer. Protein identification required at least one high-confidence peptide (FDR < 1% according to q value) and a minimum Mascot protein score of 20. Protein lists for bait and control experiments (two and three replicates, respectively) were compared in SAINTexpress with default settings 69 . External protein contaminants (such as albumin, casein and keratin) were removed from the protein identification list before further data analysis. Prey with a SAINT probability score ≥ 0.99 is reported in the final high-confidence interactors list. The complement protein C1qc was manually removed from the list because, despite having a SAINT probability of 1, it was detected with a very similar number of peptides in both bait and control samples (Supplementary Tables 15 and 16 ).
MS data analysis.
Exome sequencing. DNA from seven Utx −/− AML cases, and matched normal DNA extracted from tail tips before pIpC-mediated Utx deletion, was extracted with a DNeasy blood and tissue kit (Qiagen) according to the manufacturer's instructions. The extracted DNA was quantified (with Invitrogen's dsDNA Quant-IT PicoGreen), and each sample was then normalized to 4.17 ng/µ l in 120 µ l in preparation for library creation. The first step of library preparation involved shearing the DNA into fragments of 150 bp (with a Covaris LC220 ultrasonicator and Agilent Bravo automated workstation for liquid handling). Shearing was followed by library creation and PCR with unique index tags and adaptors (Agilent's SureSelectXT Automated Library Prep and Capture Kits and MJ Tetrad). The amplified libraries were then purified (with Agencourt AMPure XP and a Beckman Coulter Biomek NX96 for liquid handling) and eluted in nuclease-free water, and libraries were then subjected to another round of quantification (with a Caliper GX). The quantified, size-selected libraries were then diluted to an appropriate concentration for introduction into the exomecapture stage. Exome pulldown (or hybridization) was performed with Mouse-All Exon RNA-baits (designed by Agilent, supplier ID S0276129) for 23 h at 65 °C. Eight uniquely indexed samples were baited and captured in a single pool as part of the multiplexing strategy. The pulldown was then purified and eluted with streptavidin-coated Dynal beads and was ready to be amplified with PCR (MJ Tetrad). The PCR products were then further purified with Agencourt AMPure XP (and a Beckman Coulter Biomek NX96 for liquid handling), and the amplified pulldown products were quantified with an Agilent Bioanalyzer. Samples were exome sequenced as paired-end 75-bp inserts with Illumina HiSeq v4 flow-cell chemistry.
Exome data analysis. Somatic variants-point mutations and indels-were called with the Caveman 70 and Pindel 71,72 pipelines, respectively, and filtered for artifacts (including sufficient tumor fraction, strand bias and presence of the tumor allele in a panel of normal samples also sequenced at the Sanger Institute). Genome-wide copy number variation was called in the Control Freek 73 software package. This package accepts paired tumor/normal sequence files. We noticed that, in a few of our samples, the sequenced paired normal displayed an artifactual noisiness in sequencing depth; hence, we opted to use a single 'quiescent' normal (MD5280a) as a constant comparator for all samples. Control Freek was run with the following parameters: step = 1000000, window = 5000000, breakpointtype = 4, breakpointthreshold = 1.2 and readcountthreshold = 50. The copy number plots show the normalized bam depth ratio as produced by ControlFreek (black points), as well as a mark (red points) for regions marked with CopyNumber = 2. Copy number variation detection indicating a focal change at exon 3 of Utx was run (as before) with an unmatched normal (MD5280a) as well as the following parameters: step = 250, window = 500, breakpointthreshold = 0.6, breakpointtype = 4 and readcountthreshold = 50.
Statistical analysis. All statistical analyses were performed with twosided Student's t tests or one-way ANOVA, as specified in figure legends. Error bars represent the s.e.m. or the s.d. P values ≤ 0.05 were considered statistically significant. Representative data/images were replicated in at least three independent experiments, as specified in the relevant figure legend. Hypergeometric distribution was calculated with the online tool GeneProf. The number of independent experiments used to generate statistically significant data is defined in the relevant figure legends.
Reporting Summary. Further information on experimental design is available in the Nature Research Reporting Summary.
Data availability. All sequencing and proteomic raw data have been deposited in public databases. There are no restrictions to data access. The ChIP-seq and ATAC-seq data have been deposited in the GEO database under accession numbers GSE86490 and GSE101307. The exome sequencing data have been deposited in the ENA database under accession number ERP017908. MS data are available via the ProteomeXchange database under identifier PXD005011. A description of raw and processed RNA-seq files is provided in Supplementary 
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Describe how samples/organisms/participants were allocated into experimental groups.
Animals were allocated to the study groups by genotype.
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Although the investigators were not blinded to the genotype of the animals, the animal technicians who provided the animal care, supervision and identification of sick animals on "tumor watch" (therefore making the decision to sacrifice sick animals) were blinded in order to eliminate survival bias.
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Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
No unique materials were used. All antibodies used in the study were obtained commercially.
Eukaryotic cell lines
a. State the source of each eukaryotic cell line used. All cancer cell lines were obtained from the Sanger Institute Cancer Cell Collection.
b. Describe the method of cell line authentication used. Cell lines used in the study had known mutation patterns. We performed q-PCR for UTX and UTY as validation.
c. Report whether the cell lines were tested for mycoplasma contamination. No commonly misidentified cell lines were used in the study.
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Description of research animals
Provide details on animals and/or animal-derived materials used in the study.
The Utx mouse model, C57/Bl6, was developed at the Sanger Institute. Utxf/f mice were crossed with Rosa-Flpe mice and then with Mx1-Cre mice. Cre expression was induced by intra-peritoneal injection of 5-to 6-week-old mice with pIpC (Sigma #P1530, 400 μg/mouse; 5 doses over a period of 10 days). All preleukemic experiments were performed 4-6 weeks post pIpC injection. Additional blood analysis was performed at 36-weeks post pIpC. For spontaneous tumor formation mice were aged for 22 months. Cas9-expressing mice (C57/Bl6) were reported previously (Tzelepis et al., 2016) .
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Describe the covariate-relevant population characteristics of the human research participants.
The study did not involved human research participants
